C3.ai in Merger Talks With Automation Anywhere as AI Software Industry Sees Consolidation 
China Approves First Import Batch of Nvidia H200 AI Chips Amid Strategic Shift 
Sam Altman Criticizes ICE Enforcement as Corporate Leaders Call for De-Escalation 
LVMH Investors Watch Earnings Closely as Luxury Recovery Faces New Challenges 
Micron to Expand Memory Chip Manufacturing Capacity in Singapore Amid Global Shortage 
SoftBank Shares Surge as It Eyes Up to $30 Billion New Investment in OpenAI 
Woodside Energy Flags Lower 2026 Production Outlook Despite Strong Q4 Revenue Beat 
Alibaba-Backed Moonshot AI Unveils Kimi K2.5 to Challenge China’s AI Rivals 
Ford and GM Near Financing Deal to Support First Brands Group During Bankruptcy 
ASML’s EUV Lithography Machines Power Europe’s Most Valuable Tech Company 
Microsoft Wins Approval to Build 15 New Data Centers in Wisconsin 
California Governor Gavin Newsom Launches Review Into Alleged TikTok Content Suppression After U.S. Ownership Deal 
Meta Faces Lawsuit Over Alleged Approval of AI Chatbots Allowing Sexual Interactions With Minors 
Anthropic Raises 2026 Revenue Outlook by 20% but Delays Path to Profitability 
ASML’s EUV Monopoly Powers the Global AI Chip Boom 
Puma’s Historic Rivalry With Adidas Enters a New Era as Anta Deal Signals Turnaround Push 
Volkswagen CEO Oliver Blume Faces Crucial Year as Investors Demand Turnaround Results 
CAMBRIDGE, Mass., May 17, 2017 -- BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical company developing innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer, today announced that the company will present at the 2017 UBS Global Healthcare Conference in New York, NY. The presentation is scheduled for 10:30 AM ET on May 24, 2017.
A live webcast can be accessed from the investors section of BeiGene’s website at http://ir.beigene.com/. An archived replay will be available for 90 days following the event.
About BeiGene
BeiGene is a global, clinical-stage, research-based biotechnology company focused on molecularly targeted and immuno-oncology cancer therapeutics. With a team of over 400 employees in mainland China, the United States, and Australia, BeiGene is advancing a pipeline consisting of novel oral small molecules and monoclonal antibodies for the treatment of cancer. BeiGene is working to create combination solutions aimed at having both a meaningful and lasting impact on cancer patients.
Investor/Media Contact Lucy Li, Ph.D. +1 781-801-1800 [email protected] [email protected]
